0000899243-17-006216.txt : 20170302
0000899243-17-006216.hdr.sgml : 20170302
20170302205818
ACCESSION NUMBER: 0000899243-17-006216
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170228
FILED AS OF DATE: 20170302
DATE AS OF CHANGE: 20170302
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Emergent BioSolutions Inc.
CENTRAL INDEX KEY: 0001367644
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 141902018
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 400 PROFESSIONAL DR, SUITE 400
CITY: GAITHERSBURG
STATE: MD
ZIP: 20879
BUSINESS PHONE: 240-631-3200
MAIL ADDRESS:
STREET 1: 400 PROFESSIONAL DR, SUITE 400
CITY: GAITHERSBURG
STATE: MD
ZIP: 20879
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: El-Hibri Fuad
CENTRAL INDEX KEY: 0001380185
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33137
FILM NUMBER: 17661289
MAIL ADDRESS:
STREET 1: 2273 RESEARCH BLVD, SUITE 400
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-02-28
0
0001367644
Emergent BioSolutions Inc.
EBS
0001380185
El-Hibri Fuad
400 PROFESSIONAL DRIVE, SUITE 400
GAITHERSBURG
MD
20879
1
1
1
0
Chairman
Common Stock
2017-02-28
4
M
0
9722
A
1658795
D
Common Stock
2017-02-28
4
F
0
2659
30.63
D
1656136
D
Common Stock
4344250
I
By Intervac, L.L.C.
Common Stock
1524155
I
By Biovac, LLC
Restrictive Stock Units
2017-02-28
4
A
0
29382
0.00
A
Common Stock
29382
105576
D
Restrictive Stock Units
2017-02-28
4
M
0
9722
0.00
D
Common Stock
9722
95854
D
Employee Stock Option (right to buy)
30.63
2017-02-28
4
A
0
58747
0.00
A
2024-02-27
Common Stock
58747
58747
D
Restricted stock units convert into common stock on a one-for-one basis.
Mr. El-Hibri's wife, individually, and Mr. and Mrs. El-Hibri, as tenants by the entirety, collectively hold an aggregate 40.65% equity interest in Intervac, L.L.C., which in turn is the direct owner of 4,344,250 shares of the Issuer's common stock. Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Intervac, L.L.C. for purposes of Section 16 of the Exchange act or otherwise, except to the extent of his pecuniary interest therein.
Mr. El-Hibri holds individually and with his wife, as tenants by the entirety, an aggregate 89.2% equity interest in Biovac, LLC, which in turn is the direct owner of 1,524,155 shares of the Issuer's common stock. Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Biovac, LLC for purposes of Section 16 of the Exchange act or otherwise, except to the extent of his pecuniary interest therein.
In connection with the Issuer's spin-off of Aptevo Therapeutics Inc. effective on August 1, 2016 (the "Spin-off"), the Issuer made certain adjustments to the price and number of equity awards held by continuing employees. Accordingly, Mr. El-Hibri, as a continuing Emergent employee with equity awards issued prior to the Spin-off, received an equitable adjustment to the number and grant price of his restricted stock units.
On February 28, 2017, Mr. El-Hibri was granted 29,382 restricted stock units vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date.
On March 1, 2016, Mr. El-Hibri was granted 29,167 restricted stock units (after giving effect to the adjustment in connection with the Spin-off) vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date.
On February 28, 2017, Mr. El-Hibri was granted 58,747 stock options vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date.
/s/ Carl A. Valenstein, attorney-in-fact
2017-03-02